Why Global Investors Are Turning to the West Midlands for Healthcare and Life Sciences Expansion

By: Kathryn Wagstaff – Senior Business Development Manager for West midlands Growth Company

As global healthcare continues to shift toward digital-first, data-enabled, and patient-centric models, international investors are seeking scalable ecosystems that combine clinical depth, innovation infrastructure, and real-world data access. Few places in Europe offer this combination better than the West Midlands, UK.

Positioned at the beating heart of the UK, the West Midlands is rapidly becoming a strategic entry point for overseas companies expanding into the British, and broader European, life sciences market.

A Gateway to the £108 Billion UK Life Sciences Market

The UK is already home to one of the world’s most dynamic life sciences economies, valued at over £108 billion, employing nearly 300,000 people, and supported by robust government commitment. The West Midlands is at the heart of this growth, contributing £10.3 billion to the national health economy and home to over 23,000 skilled professionals in life sciences, MedTech, and digital health.

For international investors, this region presents a lower-risk, high-return environment with a clear route to scale, powered by unique health data assets, academic partnerships, and dedicated business support programmes such as the West Midlands Health Tech Innovation Accelerator.

Why Invest in the West Midlands: Key International Advantages

1. Access to One of Europe’s Most Diverse Health Data Populations

With a population of 4.7 million, the West Midlands provides one of Europe’s most diverse and demographically stable environments for health research and innovation. Overseas companies can engage with a truly representative population—ideal for clinical trials, AI training models, and personalised medicine development.

This diversity ensures that innovations developed or tested here have global relevance.

2. World-Class Clinical and R&D Infrastructure

Home to 80 hospitals and 35 clinical research centres, including Birmingham Health Partners and major NHS Trusts, the region offers streamlined access to UK clinical trials and translational medicine facilities. International companies can benefit from:

  • Faster trial start-up through dedicated trials hubs
  • Co-development with NHS hospitals and clinicians
  • Proximity to Cancer Research UK, NIHR units, and early-phase testing centres

This makes the region ideal for companies needing to validate devices, therapeutics, diagnostics, or digital health platforms before entering larger markets.

3. Health Data Assets Unmatched in Europe

Two of Health Data Research UK’s national hubs (PIONEER and INSIGHT) are located here, offering overseas investors access to some of the most trusted, de-identified clinical datasets in Europe, add to this the UK’s largest genomics facility, and international companies gain the ability to:

  • Train AI models on validated health data
  • Run real-world evidence studies in secure data environments
  • Partner with leading NHS Trusts for outcome-based research

4. Clusters with Global Appeal

The region offers purpose-built innovation campuses to help overseas businesses land, scale, and thrive as well as an array of science parks across the geography we also have:

  • Birmingham Health Innovation Campus (BHIC) – Newly opened in an established Life Sciences Opportunity Zone, with wet/dry labs, the Precision Health Technologies Accelerator (PHTA), and close ties to the University of Birmingham.
  • Coming soon: Arden Cross HealthTech Campus – A site connected to HS2 with direct links to London and Birmingham Airport making it easy for global teams to access the UK and Europe. Birmingham Knowledge Quarter (BKQ) is a distinctive and inclusive once in a generation investment opportunity with new laboratory and commercial innovation space targeted at med-/health-tech and associated clusters will be available.

International Investor Support: A Soft Landing for Global Growth

The West Midlands provides dedicated support for overseas investors, making it easy to set up, operate, and expand. The Global Growth Programme, is an initiative offering fully funded landing support for international companies, including:

  • Business incorporation advice
  • UK hiring and visas support
  • Introductions to NHS and academic partners
  • Access to public funding, including Innovate UK and NIHR grants

Other services include Investor Concierge Services, free, personalised guidance to help international investors find:

  • Suitable R&D or manufacturing space
  • Local supply chains and service partners
  • Professional advisors (legal, financial, clinical)
  • Academic or NHS co-development partners

This removes friction from market entry, so companies can focus on commercialisation and scaling.  To find out more, click here

The Talent Edge: Skilled Workforce at Global Value

With eight major universities, including four with medical schools, the region produces over 87,000 STEM graduates annually. More than 11,000 of those specialise in health, medicine, or biosciences. That is quite some talent pool!

Compared to London or other EU hubs, the West Midlands offers 30–40% lower operational costs, including:

  • Commercial real estate
  • Salary expectations
  • Lab and prototyping space

For global firms seeking to establish UK or EMEA headquarters, this translates to more efficient capital deployment without sacrificing talent access or research quality. Plus, for international teams or distributed R&D operations, the West Midlands central location with major transport hubs, means seamless travel, logistics, and collaboration.

Next Steps for International Investors

Ready to explore expansion into the UK health market through the West Midlands? Speak with the Invest West Midlands Life Sciences Team.
Kathryn Wagstaff or Yuen Wai Leung 

Position your company at the beating heart of the UK’s fastest-growing life sciences and MedTech ecosystem—where research meets market, and global becomes local.

About the author:

Kathryn Wagstaff is the Senior Business Development Manager (Life Sciences) for West Midlands Growth Company (WMGC). WMGC role is to retain and attract Life Science businesses to the West Midlands. In the blog below Kathryn gives just some of the reasons why the West Midlands is the beating heart of UKs Life Sciences developments.

For further information Kathryn.wagstaff@wmgrowth.com

Leave A Comment

    Award Category Voting

    Here's a list of all categories you can vote for. Simply click each category to cast your vote. Voting in each category is not mandatory, so please feel free to click just the category that interests you.

    Categories you've not voted in, will be denoted with an ❌

    If you're having issues submitting the form, please ensure all the category boxes are closed and try again.

    Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

    No VoteProf. Alex RichterBlack Space TechnologyAston Vision Sciences

    Celebrating an emerging leader making significant contributions to the field through research, innovation, or leadership.

    Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

    No VoteShashank Chaganty – VichagLeah Vanono - PBS InnovationsKloe Avon- KZ Organics

    Honouring successful cross-sector partnerships driving advancements in life sciences, from academia to industry.

    No VoteProf Liam Grover- WMHTIAJudith Stewart- Health Innovation West MidlandsAdam McGuinness - Plug and Play

    Awarding an individual or organisation for exceptional long-term impact on the industry.

    No VoteDavid KidneyMedilink MidlandsUniversity of Birmingham

    Highlighting innovations in treatments, diagnostics, or healthcare delivery that have significantly improved patient outcomes.

    No VoteJean-Louis Duprey - Linear DiagnosticsSian Dunning - MD-TECKarim Vissangy - HoloMedix

    Your Details